Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

by Voorhees, Peter M. , Rousseau, Els , Moreau, Philippe , Baker, Ross I. , Mylin, Anne K. , Hungria, Vania , Spicka, Ivan , Cortoos, Annelore , Goldschmidt, Hartmut , Sha, Linlin , Mikala, Gabor , Li, Liang , Lindsay, Jindriska , Mateos, Maria-Victoria , Garate, Gonzalo , Katz, Eva G. , Dimopoulos, Meletios A. , Dennis, Robyn M. , Stockerl-Goldstein, Keith , Medvedova, Eva , Cohen, Yael C. , Kosugi, Hiroshi , Theunissen, Koen , Beksac, Meral , Rajkumar, S. Vincent , Ahmadi, Tahamtan , Oriol, Albert , Cowan, Andrew J. , Bringhen, Sara , Levin, Mark-David , Schjesvold, Fredrik , Sandhu, Irwindeep , Suzuki, Kenshi , Carson, Robin , Uttervall, Katarina , Pula, Bartosz

in Adult / Adverse events / Aged / Aged, 80 and over / Antibodies, Monoclonal - administration & dosage / Antibodies, Monoclonal - adverse effects / Antineoplastic Agents - administration & dosage / Antineoplastic Agents - adverse effects / Bone marrow / CD38 antigen / Confidence intervals / Disease Progression / Female / Hematology / Humans / Immunoglobulins / Injections, Subcutaneous / Kaplan-Meier Estimate / Leukemia / Lymphoma / Male / Middle Aged / Monoclonal antibodies / Multiple myeloma / Multiple Myeloma - diagnosis / Multiple Myeloma - epidemiology / Multiple Myeloma - prevention & control / Oncology / Patients / Plasma / Progression-Free Survival / Risk assessment / Risk factors / Smoldering Multiple Myeloma - diagnosis / Smoldering Multiple Myeloma - mortality / Smoldering Multiple Myeloma - therapy / Statistical analysis / Survival / Treatments in Oncology / Watchful Waiting - statistics & numerical data

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

2025

Confirm

Do you wish to request the book?

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Voorhees, Peter M.,

Rousseau, Els,

Moreau, Philippe,

Baker, Ross I.,

Mylin, Anne K.,

Hungria, Vania,

Spicka, Ivan,

Cortoos, Annelore,

Goldschmidt, Hartmut,

Sha, Linlin,

Mikala, Gabor,

Li, Liang,

Lindsay, Jindriska,

Mateos, Maria-Victoria,

Garate, Gonzalo,

Katz, Eva G.,

Dimopoulos, Meletios A.,

Dennis, Robyn M.,

Stockerl-Goldstein, Keith,

Medvedova, Eva,

Cohen, Yael C.,

Kosugi, Hiroshi,

Theunissen, Koen,

Beksac, Meral,

Rajkumar, S. Vincent,

Ahmadi, Tahamtan,

Oriol, Albert,

Cowan, Andrew J.,

Bringhen, Sara,

Levin, Mark-David,

Schjesvold, Fredrik,

Sandhu, Irwindeep,

Suzuki, Kenshi,

Carson, Robin,

Uttervall, Katarina,

Pula, Bartosz

2025

Overview

Among patients with smoldering multiple myeloma at high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Adverse events

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal - administration & dosage

/ Antibodies, Monoclonal - adverse effects

/ Antineoplastic Agents - administration & dosage